De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy

Emerging evidence has highlighted the pathological involvement
of interleukin-11 (IL-11) in fibrotic disorders. In this study, we
identified a novel peptide antagonist 4L2 through the
random nonstandard peptide integrated discovery (RaPID) system, which
exhibits a high binding toward IL-11, with a KD value of 5.26 nM. Additionally, cell-based assays revealed
that 4L2 displays a moderate antagonistic activity, with
an IC50 value of 22.7 ± 1.9 μM. Through performing
alanine scanning and subsequent structural optimization, we developed
an improved variant, 4L2-P13D, which showed significantly
enhanced antagonistic activity, with an IC50 value of 2.8
± 0.5 μM. Furthermore, 4L2-P13D demonstrated
the significant renoprotective effects in in vitro and in vivo models. These findings indicate that
the analogue 4L2-P13D represents a promising lead candidate
for developing targeted IL-11 therapeutics against renal fibrosis.